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In Australia circa 2010, 4.1 million (90% credible interval 
[CrI] 2.3–6.4 million) episodes of foodborne gastroenteritis 
occurred, many of which might have resulted in sequelae. 
We estimated the number of illnesses, hospitalizations, and 
deaths from Guillain-Barré syndrome, hemolytic uremic 
syndrome, irritable bowel syndrome, and reactive arthritis 
that were associated with contaminated food in Australia. 
Data from published studies, hospital records, and mortality 
reports were combined with multipliers to adjust for differ-
ent transmission routes. We used Monte Carlo simulation to 
estimate median estimates and 90% CrIs. In Australia, circa 
2010, we estimated that 35,840 (90% CrI 25,000–54,000) 
illnesses, 1,080 (90% CrI 700–1,600) hospitalizations, and 
10 (90% CrI 5–14) deaths occurred from foodborne gastro-
enteritis–associated sequelae. Campylobacter spp. infec-
tion was responsible for 80% of incident cases. Reducing 
the incidence of campylobacteriosis and other foodborne 
diseases would minimize the health effects of sequelae.
Foodborne gastroenteritis is a major source of illness in Australia, causing an estimated 4.1 million (90% cred-
ible interval [CrI] 2.3–6.4 million) illnesses, 30,600 (90% 
CrI 28,000–34,000) hospitalizations, and 60 (90% CrI 
53–63) deaths each year (1). In addition to the direct ef-
fects of these illnesses, infection with some pathogens can 
result in sequelae, which can be severe, require multiple 
hospitalizations, and be costly to society (2). We report on 
the effects of sequelae associated with Guillain-Barré syn-
drome (GBS), hemolytic uremic syndrome (HUS), irritable 
bowel syndrome (IBS), and reactive arthritis (ReA) from 5 
pathogens acquired from contaminated food in Australia.
Each of these 4 sequel illnesses are preceded by differ-
ent gastrointestinal infections and have unique character-
istics. GBS, a rare but serious autoimmune illness, affects 
the nervous system and causes acute flaccid paralysis. GBS 
can occur as a sequel to Campylobacter spp. infection 10 
days–3 weeks after gastrointestinal illness (3,4). HUS is 
characterized by acute renal failure, hemolytic anemia, and 
thrombocytopenia and can result from infection with Shiga 
toxin–producing Escherichia coli (STEC) ≈4–10 days after 
onset of gastroenteritis (5,6). IBS is a gastrointestinal dis-
order that causes abdominal pain and bowel dysfunction. 
It is not life threatening, but it can cause substantial health 
effects after illness with Campylobacter spp., nontyphoidal 
Salmonella enterica serotypes (hereafter referred to as non-
typhoidal Salmonella spp.), or Shigella spp. (7,8). ReA is 
a type of spondyloarthritis that can develop up to 4 weeks 
after an enteric infection from Campylobacter spp., nonty-
phoidal Salmonella spp., Shigella spp., or Yersinia entero-
colitica (9). We estimated the number of illnesses, hospi-
talizations, and deaths resulting from GBS, HUS, IBS, and 
ReA from selected foodborne pathogens in Australia in a 
typical year circa 2010.
Methods
We estimated the effects of foodborne sequelae ac-
quired in Australia circa 2010 using data from multiple 
sources in Australia and from international peer-reviewed 
literature. We defined foodborne sequelae as illnesses oc-
curring after bacterial gastroenteritis caused by eating con-
taminated food. Sequelae were defined as the secondary 
adverse health outcomes resulting from a previous infec-
tion by a microbial pathogen and clearly distinguishable 
from the initial health event (10). Illness can be acute, such 
as with HUS, or chronic (lasting for many years), as with 
IBS. We estimated incidence, hospitalizations, and deaths 
with uncertainty bounds using Monte Carlo simulation in 
@Risk version 6 (http://www.palisade.com/), which incor-
porates uncertainty in both data and inputs. Each stage of 
our calculation was represented by a probability distribu-
tion, and our final estimates of incidence, hospitalizations, 
and deaths were summarized by the median and 90% CrI. 
Similar to a recent study in the United States (11), we used 
empirical distributions for source distributions, such as the 
number of hospitalizations or deaths, to avoid assumptions 
about the expected shape of these distributions. All other 
inputs were modeled by using the PERT (project evalua-
tion and review technique) distribution, which enables the 
input of a minimum, maximum, and modal value, or 3 per-
centile points, such as a median value and 95% bounds. 
We used this distribution widely in our analyses because 
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it enables asymmetric distributions and can be produced 
from many data sources, including expert elicitation data. 
The Australian National University Human Research Eth-
ics Committee approved the study.
Incidence of Sequelae
Several pathogens are associated with the develop-
ment of sequelae. Community estimates of foodborne 
illness from Kirk et al. (1) for Campylobacter spp., non-
typhoidal Salmonella spp., Shigella spp., STEC, and Y. 
enterocolitica were used for estimating the incidence of 
foodborne sequelae (Table 1). Although Shigella spp. and 
nontyphoidal Salmonella spp. have been associated with 
HUS and STEC has been associated with IBS and ReA, 
data on which to base estimates are limited. In addition, 
although other pathogens, such as Chlamydia trachoma-
tis, Clostridium difficile, Giardia lamblia, and norovi-
rus, have been associated with these sequelae (12–15), 
we assessed only pathogens commonly associated with 
sequelae, domestically acquired, and with a foodborne 
transmission pathway. A “sequelae multiplier,” which is 
the proportion of sequelae cases that develop after enteric 
infection with a specific bacterial pathogen, was applied 
to our estimates of domestically acquired foodborne gas-
troenteritis cases caused by that pathogen (1). For each 
sequel illness, we reviewed relevant studies published 
during 1995–2012 using systematic reviews and studies 
using Australian data where possible to estimate the rel-
evant sequelae multipliers. We reviewed articles about 
sequelae after infection with Campylobacter spp., E. coli, 
nontyphoidal Salmonella spp., Shigella spp., and Y. en-
terocolitica, and we estimated sequelae multipliers for 
GBS, HUS, IBS, and ReA after bacterial gastrointestinal 
infection on the basis of these reviews (Table 2). Relevant 
articles and additional information are documented in on-
line Technical Appendix 1 (http://wwwnc.cdc.gov/EID/
article/20/11/13-1316-Techapp1.pdf).
Our sequelae multiplier for GBS was based on 30.4 
(range 19.2–94.5) cases of GBS per 100,000 cases of 
campylobacteriosis using data from studies from the 
United Kingdom, Sweden, and the United States (16–18). 
For HUS, the sequelae multiplier used was 3% (95% CI 
1.7%–5.4%) from a South Australian study on STEC and 
HUS notifications during 1997–2009 (19). On the ba-
sis of data from Haagsma et al. (20), we assumed that 
8.8% (95% CI 7.2%–10.4%) of foodborne disease caused 
by Campylobacter spp., nontyphoidal Salmonella spp., 
and Shigella spp. result in IBS. We used a separate se-
quelae multiplier for each pathogen that resulted in ReA. 
We assumed that 7% (range 2.8%–16%) of foodborne 
cases of Campylobacter spp., 8.5% (range 0%–26%) of 
foodborne cases of nontyphoidal Salmonella spp., 9.7% 
(range 1.2%–9.8%) of foodborne cases of Shigella spp., 
and 12% (range 0%–23.1%) of foodborne cases of Y. en-
terocolitica result in ReA (see full reference list in online 
Technical Appendix 1). Total foodborne IBS and ReA 
cases reflect the sum of modeled IBS and ReA cases from 
these 3 and 4 pathogens, respectively. Details on the se-
quelae multipliers and incidence estimation methods are 
in online Technical Appendix 1 and online Technical Ap-
pendix 2 (http://wwwnc.cdc.gov/EID/article/20/11/13-
1316-Techapp2.pdf).
We compared the incidence of sequelae circa 2010 to 
that of sequelae circa 2000 by applying the same sequelae 
multipliers to estimates of the incidence of acute gastroen-
teritis to specific pathogens in 2006–2010 and 1996–2000, 
respectively. The estimates of incidence of acute gastroen-
teritis were based on notification data for Campylobacter 
spp., nontyphoidal Salmonella spp., Shigella spp., STEC, 
and Y. enterocolitica (19,21,22), (online Technical Appen-
dix 3, http://wwwnc.cdc.gov/EID/article/20/11/13-1316-
Techapp3.pdf).
Hospitalizations and Deaths
To estimate hospitalizations associated with IBS from 
foodborne Campylobacter spp., nontyphoidal Salmonella 
spp., and Shigella spp. and hospitalizations associated with 
ReA from foodborne Campylobacter spp., nontyphoidal 
Salmonella spp., Shigella spp., and Y. enterocolitica, we 
used hospitalization data for 2006–2010 from all Australian 
states and territories, according to the International Clas-
sification of Diseases, Tenth Revision, Australian Modi-
fication (ICD-10-AM) codes. To estimate deaths for all 4 
Table 1. Pathogens associated with GBS, HUS, IBS, and ReA 
included in this study, Australia, circa 2010* 
Pathogen GBS HUS IBS ReA 
Campylobacter spp. X  X X 
Nontyphoidal Salmonella spp.†   X X 
Shigella spp.   X X 
Shiga toxin–producing Escherichia 
coli 
 X   
Yersinia enterocolitica    X 
*GBS, Guillain-Barré syndrome; HUS, hemolytic uremic syndrome; IBS, 
irritable bowel syndrome; ReA, reactive arthritis. 
†Nontyphoidal S. enterica serotypes. 
 
 
Table 2. Sequelae multipliers extracted from the literature about 
domestically acquired foodborne bacterial gastroenteritis* 
Sequelae 
ICD-10-AM 
code 
Incidence after bacterial 
infection, % 
GBS, median (range) G61.0 0.0304 (0.0192–0.0945) 
HUS, median (95% CI) D59.3 3 (1.7–5.1) 
IBS, median (90% CrI) K58.0 8.8 (7.2–10.4) 
 K58.9  
ReA, median (range) M02.1 7–12 (0–26) 
 M02.3  
 M02.8  
 M03.2  
*CrI. credible interval; GBS, Guillain-Barré syndrome; HUS, hemolytic 
uremic syndrome; IBS, irritable bowel syndrome; ICD-10-AM, International 
Classification of Diseases, Tenth Revision, Australian Modification; ReA, 
reactive arthritis. 
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sequelae illnesses resulting from the respective foodborne 
pathogens, we used national death data for 2001–2010 
from the Australian Bureau of Statistics, using ICD-10-
AM codes (online Technical Appendix 4, http://wwwnc.
cdc.gov/EID/article/20/11/13-1316-Techapp4.pdf). Princi-
pal diagnosis and additional diagnoses were included for 
hospitalizations, and underlying and contributing causes 
were included for deaths. Because we had only 1 year of 
hospitalization data for Victoria and 2 years for New South 
Wales, we extrapolated from these data to derive a distri-
bution of the number of hospitalizations across all states, 
which was modeled as an empirical distribution. For these 
states, we assumed the same number of hospitalizations 
each year to adjust for missing data. Because of the sever-
ity of GBS and HUS, hospitalization estimates for these 
illnesses were not modeled, and all persons with estimated 
incident cases from contaminated food were considered to 
have been hospitalized.
We estimated incidences of hospitalization and death 
using a statistical model that incorporates uncertainty in 
case numbers and in multipliers using probability distribu-
tions (Figure), which is adjusted from the hospitalization 
estimation flow chart in Kirk et al. (1). We assumed that 
all estimated incident foodborne Campylobacter-associ-
ated GBS and STEC-associated HUS case-patients were 
hospitalized, so those cases were not modeled; however, 
multipliers were still needed for GBS and HUS to estimate 
deaths. Sequelae-associated deaths were estimated by us-
ing the same methods as for hospitalizations (Figure). Input 
data arose from the data sources discussed above or from 
multipliers that are discussed below.
Domestically Acquired Multiplier
The “domestically acquired multiplier” adjusted for 
the proportion of case-patients who acquired their infec-
tion in Australia. We estimated domestically applied mul-
tipliers for the antecedent bacterial gastrointestinal patho-
gens using notifiable surveillance data from each state, 
extrapolated to give national estimates (1). We adopted 
the domestically acquired multiplier for Campylobacter 
spp. of 0.97 (90% CrI 0.91–0.99) for GBS and the do-
mestically acquired multiplier for STEC 0.79 (90% CrI 
0.73–0.83) for HUS (1). For IBS and ReA, a combined 
domestically acquired multiplier for Campylobacter spp., 
nontyphoidal Salmonella spp., and Shigella spp. for IBS 
and Campylobacter spp., nontyphoidal Salmonella spp., 
Shigella spp. and Y. enterocolitica for ReA was calculated 
as a weighted average of the domestically acquired mul-
tipliers for each pathogen, weighted by the total number 
of IBS and ReA cases for each pathogen, respectively 
(online Technical Appendix 4; online Technical Appen-
dix 5, http://wwwnc.cdc.gov/EID/article/20/11/13-1316-
Techapp5.pdf).
Proportion Foodborne Multiplier
For each of the 4 sequelae, we calculated the proportion 
of hospitalizations and deaths from foodborne pathogens 
using 2 multipliers: a “bacterial multiplier” to attribute the 
proportion of overall cases of each of the sequelae illnesses 
to specific pathogens and a “foodborne multiplier” to attri-
bute illnesses to foodborne exposure. The bacterial multi-
plier, which was the proportion of sequel cases attributable 
to their antecedent bacterial pathogen, was extracted from 
systematic reviews for GBS and HUS (4,23) and multiplied 
by the foodborne proportion for Campylobacter spp. and 
STEC, respectively. For IBS and ReA, from the literature 
we extracted a midpoint and range of the proportion of cas-
es that resulted from infectious gastroenteritis (12,20,24). 
The IBS bacterial multiplier was then further multiplied by 
a foodborne multiplier for Campylobacter spp., nontyphoi-
dal Salmonella spp., and Shigella spp., which was calcu-
lated as a weighted average of the foodborne multipliers for 
each pathogen, weighted by the total number of IBS cases 
for each pathogen. The ReA bacterial multiplier was then 
also multiplied by the foodborne multiplier for Campylo-
bacter spp., nontyphoidal Salmonella spp., Shigella spp., 
and Y. enterocolitica by using a weighted average of the 
foodborne multipliers for each pathogen as was done for 
IBS (online Technical Appendices 4 and 5).
Figure. Flow chart for the approach used to calculate the estimated 
annual number of hospitalizations for sequelae associated with 
foodborne illness caused by 5 pathogens, Australia, circa 2010.
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Results
Incidence
We estimated that, circa 2010 in Australia, 70 (90% 
CrI 30–150) new cases of Campylobacter-associated GBS, 
70 (90% CrI 25–200) new cases of STEC-associated HUS, 
19,500 (90% CrI 12,500–30,700) new cases of Campylo-
bacter-, nontyphoidal Salmonella– and Shigella-associated 
IBS, and 16,200 (90% CrI 8,750–30,450) new cases of 
Campylobacter-, nontyphoidal Salmonella-, Shigella-, and 
Y. enterocolitica–associated ReA were domestically ac-
quired and caused by contaminated food (Table 3). We es-
timated that 35,840 (90% CrI 25,000–54,000) domestically 
acquired sequel illnesses resulted from foodborne gastroen-
teritis—an incidence rate of 1,620 (90% CrI 1,150–2,450) 
sequelae cases per million population. Campylobacter spp. 
infection resulted in the largest number of sequelae cases 
annually; ≈80% of the 36,000 sequel illnesses were attrib-
utable to Campylobacter spp. alone.
Comparison with Estimates Circa 2000
Using data circa 2000, we estimated that 50 GBS cas-
es, 55 HUS cases, 14,800 IBS cases, and 12,500 ReA cases 
occurred each year. Elsewhere, we estimated that the rate 
of foodborne campylobacteriosis was approximately 13% 
higher in 2010 than 2000 (1); this increase led to a 13% 
increase in Campylobacter-associated GBS in 2010 over 
2000. Similarly, we estimated that the rate of foodborne 
salmonellosis was 24% higher in 2010 than in 2000 (1). 
These factors combine to explain much of the increase in 
IBS and ReA. The rate of STEC-associated HUS remained 
about the same in 2000 and 2010 (online Technical Ap-
pendix 3).
Hospitalizations and Deaths
We estimated that, circa 2010 in Australia, 1,080 (90% 
CrI 700–1,600) hospitalizations for sequelae illnesses oc-
curred from domestically acquired foodborne gastroenteri-
tis, equating to 50 (90% CrI 30–70) hospitalizations per 
million population per year (Table 4). We estimated a total 
of 10 (90% CrI 5–14) deaths from sequelae to domestically 
acquired foodborne gastroenteritis—a rate of 0.5 (90% CrI 
0.2–0.6) deaths per million population per year (Table 4).
Discussion
Our study demonstrates that foodborne gastroenteritis 
in Australia results in substantial severe and disabling se-
quelae. We estimated a yearly rate of 1,620 incident cases 
of sequelae illnesses, 50 hospitalizations, and 0.5 deaths 
per million population circa 2010. In addition, a compari-
son with estimates recalculated for 2000 indicates an in-
crease in the rates of GBS, IBS, and ReA since 2000, which 
is consistent with and directly related to rising levels of 
antecedent foodborne illnesses caused by Campylobacter 
spp. and nontyphoidal Salmonella spp. during this period 
(1). This increase highlights the importance of quantifying 
sequelae when estimating the effects of foodborne disease 
and provides further impetus for reducing illness from 
foodborne bacterial pathogens.
The impact of Campylobacter spp. infection in the 
community is high. Approximately 179,000 cases of food-
borne campylobacteriosis occur in Australia each year (1), 
and Campylobacter spp. was responsible for 80% of the 
foodborne sequelae illness estimated in this study. The 
reported rate of infection from Campylobacter spp. in 
Australia has increased since 2010 (1) and is higher than 
in many other industrialized countries. For example, the 
rate of Campylobacter spp. for Australia was ≈10 times 
higher than that for the United States (25), double that for 
the Netherlands (26), and slightly higher than that for the 
United Kingdom (27). In the Netherlands, a lower rate of 
acute Campylobacter spp. gastroenteritis has contributed to 
lower estimates of rates of sequel illnesses than our esti-
mates for GBS, IBS, and ReA (26).
In New Zealand, food safety interventions have been 
effective in lowering campylobacteriosis rates and se-
quelae. In 2006, high campylobacteriosis notification rates 
(>3,800 cases per million population) prompted increased 
research on Campylobacter spp., which resulted in the 
introduction of food safety and poultry industry interven-
tions, including Campylobacter spp. performance targets 
at primary processing plants and promotion of freezing all 
fresh poultry meat (28). By 2008, the rate of campylobac-
teriosis notifications decreased by 54% to 1,615 cases per 
million population (28). In addition, after these interven-
tions in New Zealand, the rate of GBS hospitalizations de-
creased by 13% (29). The less dramatic decrease in GBS 
than in campylobacteriosis might be explained by the fact 
that Campylobacter spp. is not the only cause of GBS. If 
Australia were to experience decreases similar to those 
in New Zealand, we would expect the rate of foodborne 
campylobacteriosis in the community to drop from approx-
imately 8,400 to 3,864 cases per million population. Se-
quelae would decrease from 1,620 to 870 cases per million 
population per year. Furthermore, total GBS-associated 
hospitalizations, including GBS from all causes and read-
missions, would decrease from ≈73 to 63 hospitalizations 
per million population annually.
A comparison of our foodborne Campylobacter-as-
sociated GBS incidence estimates with raw hospitaliza-
tion data showed many more hospitalizations than incident 
cases. This finding probably is attributable to repeat hos-
pitalizations. We took a conservative approach by basing 
incidence estimates on community estimates of campy-
lobacteriosis and assuming that all persons with incident 
cases were hospitalized. A yearly median of 1,536 (range 
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1,428–1,632) primary and additional GBS diagnoses oc-
curred in Australian hospitals during 2006–2010 (includ-
ing GBS from all causes and readmissions) and equates to 
a median rate of 73.1 (range 64.7–77.4) GBS-associated 
hospitalizations per million population each year. This rate 
is within the range from a New Zealand study, which found 
a median rate of 56.3 (range 42.1–75.9) GBS-associated 
hospitalizations during a 13-year period, with ≈41% of 
case-patients being readmitted, resulting in 23.2 (range 
15.3 29.3) incident GBS hospitalizations per million popu-
lation each year (29). If we assume that 41% of Australia’s 
1,536 GBS hospitalizations are readmissions and apply the 
domestically acquired multiplier and foodborne proportion 
multiplier used to estimate GBS-associated deaths (online 
Technical Appendix 4), we would estimate 170 (90% CrI 
60–265) incident foodborne Campylobacter-associated 
GBS hospitalizations. This point estimate is higher than our 
current estimate of 70, although the credible interval in-
cludes our estimate. A validation study of medical records 
of persons with GBS would enable us to better characterize 
readmissions for GBS.
Our approach has several limitations. First, our com-
parison of sequelae estimates for 2000–2010 assumes a 
constant rate of sequelae illness after gastrointestinal infec-
tion over time. Although our methods provide an indirect 
method of assessing changes in sequelae incidence over 
time, the approach is useful because it enables comparison 
of the population-level effect of sequelae at these 2 time 
points. Second, our study measured incidence and not 
prevalence of sequelae. We estimated the number of new 
cases every year and did not quantify the long-term effects 
of these sequelae. Third, our study does not estimate all 
sequelae illness from foodborne disease pathogens. We 
did not include sequelae, such as end-stage renal disease, 
inflammatory bowel disease, and encephalitis, in our esti-
mates. We chose GBS, HUS, IBS, and ReA for this study 
because they were known, well studied, and well character-
ized in available data sources. These provide a good basis 
to begin to understand the effects of foodborne sequelae 
and the policy implications of reducing illness from pre-
ceding bacterial pathogens.
Our estimates for GBS, HUS, IBS, and ReA incidence 
relied heavily on the quality of the literature we reviewed. 
We used Australian data and systematic reviews wherever 
possible. The Australian hospitalization and deaths data we 
used were of high quality and included both principal and 
additional diagnoses from all states. However, because data 
were missing from some states in some years, we extrapo-
lated from these data to the remaining years. Finally, ICD-10 
and ICD-10-AM coding can be problematic when co-morbid 
conditions are present, when hospital transfers occur, or when 
diagnostic criteria are inconsistent. Therefore, our estimates 
for sequelae hospitalizations and deaths may be conservative 
because they do not account for these coding errors.
 
Table 3. Estimated number of sequelae illnesses resulting from domestically acquired foodborne bacterial gastroenteritis, Australia, 
circa 2010* 
Sequelae, pathogen Median no. Illnesses (90% CrI) Median rate (90% CrI)† 
GBS, Campylobacter spp. 70 (30–150) 3.1 (2–6) 
HUS, STEC 70 (25–200) 3.3 (1–9) 
IBS   
 Campylobacter spp 15,600 (9,000–26,500) 915 (570–1,440) 
 Nontyphoidal Salmonella spp.‡ 3,500 (1,900–6,500)  
 Shigella spp. 30 (10–80)  
 Total§ 19,500 (12,500–30,700)  
ReA   
 Campylobacter spp. 12,500 (5,500–25,500) 765 (415–1,375) 
 Nontyphoidal Salmonella spp.‡ 3,250 (700–9,000)  
 Shigella spp. 29 (10–75)  
 Yersinia enterocolitica 150 (50–300)  
 Total§ 16,200 (8,500–30,000)  
Total 35,840 (25,000–54,000) 1,620 (1,150–2,450) 
*CrI, credible interval; GBS, Guillain-Barré syndrome; HUS, hemolytic uremic syndrome; IBS, irritable bowel syndrome; ReA, reactive arthritis; STEC, 
Shiga toxin–producing Escherichia coli. 
†No. cases per million population. 
‡i.e., nontyphoidal S. enterica serotypes. 
§Simulated values, which might not add to total because of rounding and variation over simulations. 
 
 
Table 4. Estimated number of sequelae-associated hospitalizations and deaths caused by domestically acquired foodborne bacterial 
gastroenteritis, Australia, circa 2010* 
Sequelae 
Hospitalizations  Deaths 
Median no. (90% CrI) Rate (90% CrI)† Median no. (90% CrI) Rate (90% CrI)† 
GBS 70 (30–150) 3.1 (2–6)  6 (2–10) 0.3 (0.1–0.5) 
HUS 70 (25–200) 3.3 (1–9)  2 (1–3) 0.1 (0.03–0.12) 
IBS 915 (550–1,400) 43 (25–70)  2 (1–2) 0.1 (0.05–0.11) 
ReA 25 (20–40) 1 (1–2)  0 0 
Total 1,080 (700–1,600) 50 (30–70)  10 (5–14) 0.5 (0.2–0.6) 
*CrI, credible interval. GBS, Guillain-Barré syndrome; HUS, hemolytic uremic syndrome; IBS, irritable bowel syndrome; ReA, reactive arthritis; STEC, 
Shiga toxin–producing Escherichia coli. 
†Cases per million population. 
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The sequelae estimates from this study showed that the 
impact of foodborne Campylobacter spp., nontyphoidal Sal-
monella spp., Shigella spp., STEC, and Y. enterocolitica was 
much greater then when consideration is given simply to the 
initial acute illness. Campylobacter spp. infection, in partic-
ular, was highlighted as an increasing problem in Australia. 
Our estimates provide a basis for costing studies, which can 
be useful for developing food safety policies and interven-
tions. Finally, our study highlights the need for better data 
from large population-based studies in Australia to further 
characterize sequelae, as well as foodborne pathogens.
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